small meaning percentag men who treat extern beam radiat therapi prostat cancer develop late gastrointestin toxic while numer strategi prevent gastrointestin injuri have been studi clinic trial concentr late toxic have been difficult carri out identif subject high risk late gastrointestin injuri could allow toxic prevent trial perform use reason sampl size acute radiat therapi toxic has been shown predict late toxic sever organ system late toxic may occur consequenti effect acut injuri systemat review publish report found late gastrointestin toxic follow prostat radiotherapi seem statist potenti causal relat acut gastrointestin morbid consequenti effect submit acut gastrointestin toxic may use identifi atrisk patient who may benefit from addit attent medic intervent close followup prevent late toxic acute gastrointestin toxic could also explor surrog endpoint late effect prospect trial

Matthew Sean Peach

Timothy N. Showalter

Nitin Ohri

Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer

purpos atypic small acinar prolifer asap diagnos 12 prostat biopsi 3040 patient asap may diagnos prostat cancer pca repeat biopsi our object examin associ between asap subsequ diagnosi intermedi high risk pca materi method ninetysix patient who underw prostat biopsi from 2000 2013 were diagnos asap were identifi clinicopatholog featur were analyz comparison made between those subsequ pca repeat biopsi those benign repeat patholog result 5696 58 patient had repeat biopsi 2256 39 were subsequ diagnos pca there signific differ patient characterist presenc hgpin initi biopsi associ benign repeat biopsi 68 versus 23 1722 77 had gleason grade 3 3 diseas onli 522 23 had 3 4 diseas conclus 2256 patient 39 patient who underw subsequ prostat biopsi follow diagnosi asap were found have pca 77 men were diagnos 3 3 pca onli 23 were found have intermedi risk pca high risk pca identifi immediat repeat prostat biopsi patient diagnos asap may safe delay multiinstitut cohort be analyz

Andrew Leone

Katherine Rotker

Christi Butler

Anthony Mega

Jianhong Li

Ali Amin

Stephen F. Schiff

Gyan Pareek

Dragan Golijanin

Joseph F. Renzulli

Atypical Small Acinar Proliferation: Repeat Biopsy and Detection of High Grade Prostate Cancer

background prostat cancer most common noncutan cancer second lead caus cancerrel mortal men grow evid suggest oxid stress involv prostat cancer method studi thioredoxin 1 trx 1 enzym subcellular indic redox status measur prostat biopsi tissu from 55 men from north carolinalouisiana prostat cancer project pathologist blind score level trx 1 the associ between trx 1 gleason score erythrocyt antioxid enzym activ dietari antioxid intak determin use fisher exact test result trx 1 level benign prostat tissu men incid prostat cancer were posit associ gleason score invers associ dietari antioxid intak prostat cancer tissu trx 1 level were associ erythrocyt glutathion peroxidas activ associ found other erythrocyt enzym greater gleason score malign tissu correspond greater differ trx 1 level between malign benign tissu conclus these result suggest redox status prostat tissu associ prostat cancer grade both endogen exogen antioxid

Terrence M. Vance

Gissou Azabdaftari

Elena A. Pop

Sang Gil Lee

L. Joseph Su

Elizabeth T. H. Fontham

Jeannette T. Bensen

Susan E. Steck

Lenore Arab

James L. Mohler

Ming-Hui Chen

Sung I. Koo

Ock K. Chun

Thioredoxin 1 in Prostate Tissue Is Associated with Gleason Score, Erythrocyte Antioxidant Enzyme Activity, and Dietary Antioxidants

genomewid associ studi gwas have implic singl nucleotid polymorph snps chromosom 2p15 6q25 7p152 7q21 8q24 10q11 10q26 11q13 17q12 17q24 19q13 xp11 prostat cancer pca suscept tumour aggress popul african european asian ancestri the object studi confirm associ south african mix ancestri white men evalu 17 prioritis gwas snps south african case 331 mix ancestri 155 white control 178 mix ancestri 145 white the replic snp associ differ south african ethnic group were rs7008482 8q24 rs6983267 8q24 rs10993994 10q11 mix ancestri men rs10993994 white men signific associ were observ analys stratifi diseas aggress individu combin popul group analysi the present studi demonstr number known pca suscept variant may contribut diseas suscept south african men larger genet investig extend other south african popul group warrant confirm role other snps diseas suscept

Pedro Fernandez

Muneeb Salie

Danielle du Toit

Andre van der Merwe

Analysis of Prostate Cancer Susceptibility Variants in South African Men: Replicating Associations on Chromosomes 8q24 and 10q11

objectiv describ urologist practic pattern when manag patient advanc prostat cancer pca spain method this observ studi conduct 120 urologist use retrospect data advanc pca patient attend hospit outpati center result urologist evalu total 375 patient mean age 75 year ecog 01 77 mean serum psa level studi entri 505 approxim 50 patient had bone metastas 606 experienc pain main symptom progress diseas primari androgen depriv therapi adt use 997 continu adt domin strategi 919 after failur initi adt antiandrogen withdraw next method most common use 57 patient choic secondari hormon treatment made most urologist 96 who continu monitor patient patient followup after chemotherapi support care were main done urolog unit although respons share medic oncologist radiologist conclus the urologist attitud toward manag pca routin practic spain show urologist integr compon even when patient progress advanc stage diseas

Maria José Ribal

Juan Ignacio Martínez-Salamanca

Camilo García Freire

Current Patterns of Management of Advanced Prostate Cancer in Routine Clinical Practice in Spain

purpos experiment data suggest tumour cell can revers transit between epitheli mesenchym state emt met phenomenon known cellular plastic the aim review apprais clinic evid role cellular plastic prostat cancer bone metastasi method electron search perform use pubm studi have examin differenti express epitheli mesenchym stem cell marker human bone metastasi tissu result the review includ nineteen studi more than 60 studi use 20 bone metastasi sampl were sever sourc heterogen between studi overal most stem cell marker analys except cxcr4 were posit express bone metastasi tissu while express emt met marker heterogen between within sampl sever emt stem marker involv osteomimicri notch met receptor wnt pathway were high express bone metastas conclus clinic find support role cellular plastic bone metastasi suggest epitheli mesenchym state cannot taken isol when target bone metastasi the paper also highlight sever challeng clinic detect cellular plastic

Dima Y. Jadaan

Mutaz M. Jadaan

John P. McCabe

Cellular Plasticity in Prostate Cancer Bone Metastasis

introduct prostat cancer most common cancer among men usa the surgic outcom prostat cancer remain inconsist barrier socioeconom factor may play role patient decis refus recommend cancerdirect surgeri method the nebraska cancer registri data use calcul proport prostat cancer patient recommend cancerdirect surgeri surgeri refus rate multivari logist regress appli analyz socioeconom indic were relat refus surgeri result from 1995 2012 14876 prostat cancer patient were recommend undergo cancerdirect surgeri nebraska 576 them refus surgeri the overal refus rate surgeri 39 over 18 year patient earlystag prostat cancer were more like refus surgeri patient who were black singl cover medicaid medicar had increas odd refus surgeri conclus socioeconom factor were relat refus recommend surgic treatment prostat cancer such barrier should address improv util surgic treatment patient wellb

K. M. Islam

Jiajun Wen

Prostate Cancer Patients&#x2019; Refusal of Cancer-Directed Surgery: A Statewide Analysis

background new nontox target approach need patient castrat resist prostat cancer crpc our preclin studi show activ cell atc arm anticd3 antiher2 bispecif antibodi her2bi kill prostat cancer cell line induc 1 cytokin pattern upon engag tumor cell prevent develop prostat tumor retard tumor growth immunodefici mice these studi provid strong rational our phase doseescal pilot studi test atc arm her2bi aatc safeti men crpc method seven 8 men crpc were evalu after receiv two infus per week 4 week the men receiv 25 5 10 10 9 aatc per infus low dose interleukin2 granulocytemacrophag coloni stimul factor result there were dose limit toxic 1 partial respond 3 7 patient had signific decreas psa level pain score immune evalu peripher blood mononuclear cell 2 patient befor after immunotherapi show increas ifn elispot respons 1 serum cytokin conclus these result provid strong rational develop phase trial determin whether aatc effect treat crpc

Ulka Vaishampayan

Archana Thakur

Ritesh Rathore

Nicola Kouttab

Lawrence G. Lum

Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

this prospect nonintervent openlabel multicentr belgian studi assess preval moder sever lower urinari tract symptom luts patient local advanc metastat prostat cancer schedul receiv triptorelin therapi it effect luts were evalu focus symptom relief chang qualiti life qol relat urinari symptom novemb 2006 may 2010 inclusion criteria were age 18 year histolog confirm advanc metastat prostat cancer life expect 12 month exclusion criteria were treatment ani lhrh analogu within last 6 month ani other investig agent within last 3 month befor studi entri patient who receiv one more triptorelin dose had one more efficaci assess were evalu total 325 patient were includ median age 74 year 50 95 year mean age first diagnosi year moder ipss 819 sever ipss 20 luts were observ 62 patient triptorelin reduc luts sever this improv perceiv within first 24 week treatment maintain after 48 week decreas psa level also observ

Alexandre Peltier

Fouad Aoun

Vincent De Ruyter

Patrick Cabri

Roland Van Velthoven

Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study

About this journal

Prostate Cancer provides a multidisciplinary platform for scientists, surgeons, oncologists and clinicians working on prostate cancer. Research includes diagnosis, surgery, radiotherapy, drug discovery and medical management of the disease.

Journal profile

Meet the editorial board

Prostate Cancer maintains an Editorial Board of practicing researchers from around the world, to ensure manuscripts are handled by editors who are experts in the field of study.

Editor spotlight

Submit your proposal

Do you think there is an emerging area of research that really needs to be highlighted? Or an existing research area that has been overlooked or would benefit from deeper investigation? Raise the profile of a research area by leading a Special Issue.

Special Issues

Author guidelines

Editorial board

Databases and indexing

title

Prostate Cancer provides a multidisciplinary platform for scientists, surgeons, oncologists and clinicians working on prostate cancer. Research includes diagnosis, surgery, radiotherapy, drug discovery and medical management of the disease.

Prostate Cancer